Heat Biologics (NASDAQ: HTBX), a prerevenue biotech, is off to a strong start today. The company's shares spiked by as much as 46% in early-morning trading in response to a positive update for its experimental COVID-19 vaccine.
Specifically, Heat announced that its COVID-19 vaccine candidate exhibited compelling evidence of immunogenicity (the ability to provoke a body's immune response) in a preclinical (animal) study. Although the biotech's shares have cooled off a bit over the course of today's session, they are still up by a noteworthy 20% as of 10:56 a.m. EDT.
Image Source: Getty Images.